Skip to main content
Retour
Watch Compare

Aptevo Therapeutics Inc.

Qualité des données : 83%
APVO
Nasdaq Manufacturing Chemicals
4,37 €
▲ 0,09 € (2,10%)
Cap. Boursière: 5,16 M
Prix
4,37 €
Cap. Boursière
5,16 M
Fourchette du Jour
4,25 € — 4,38 €
Fourchette 52 Semaines
3,80 € — 486,00 €
Volume
15 186
Ouverture 4,35 €
Moyenne 50J / 200J
6,06 €
27,90% below
Moyenne 50J / 200J
25,19 €
82,65% below

Quick Summary

Points Clés

Negative free cash flow of -25,59 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-217,15%
En dessous de la moyenne du secteur (-53,41%)
ROIC-129,45%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio4,03
Interest CoverageN/A

Valorisation

PE (TTM)
-0,20
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio0,30
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -0,2 -1,5
P/B 0,3 1,6
ROE % -217,2 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -25,97 M
ROE -217,15% ROA -121,85%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -25,59 M
ROIC -129,45% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4,03
Interest Coverage N/A Asset Turnover N/A
Working Capital 17,04 M Tangible Book Value 17,39 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,20 Forward P/E N/A
P/B Ratio 0,30 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -495,57%
Market Cap 5,16 M Enterprise Value -15,90 M
Per Share
EPS (Diluted TTM) -87,27 Revenue / Share N/A
FCF / Share -21,66 OCF / Share -21,66
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 98,56%
SBC-Adj. FCF -25,84 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — 3,11 M 3,11 M 12,29 M
Net Income -25,97 M -24,13 M -17,41 M 8,03 M -28,46 M
EPS (Diluted) -87,27 -87,38 -1,42 1,57 —
Gross Profit — — — — —
Operating Income -26,31 M -24,60 M -28,88 M -28,64 M -21,40 M
EBITDA — — — — —
R&D Expenses 14,54 M 14,38 M 17,11 M 17,88 M 18,99 M
SG&A Expenses — — — — —
D&A 240 000,0 352 000,0 567 000,0 901 000,0 1,14 M
Interest Expense — — — — —
Income Tax 0,0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 27,19 M 15,59 M 24,84 M 34,22 M 56,60 M
Total Liabilities 9,81 M 10,84 M 12,62 M 16,24 M 55,39 M
Shareholders' Equity 17,38 M 4,76 M 12,22 M 17,97 M 1,22 M
Total Debt — — 0,0 4,01 M 16,02 M
Cash & Equivalents 21,62 M 8,71 M 16,90 M 22,64 M 45,04 M
Current Assets 23,08 M 10,66 M 19,07 M 27,45 M 52,57 M
Current Liabilities 6,05 M 6,21 M 7,22 M 8,71 M 34,76 M